These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18489402)

  • 41. [Peg-interferon alfa-2a and highly active antiretroviral drug therapy on hepatitis C patients with AIDS].
    Zhang RF; Sun HQ; Huang Q; Wang JR; Zhang XX; Liu XN; Lu HZ
    Zhonghua Gan Zang Bing Za Zhi; 2007 Oct; 15(10):734-7. PubMed ID: 17963597
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence.
    Coilly A; Furlan V; Roche B; Barau C; Noël C; Bonhomme-Faivre L; Antonini TM; Roque-Afonso AM; Samuel D; Taburet AM; Duclos-Vallée JC
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5728-34. PubMed ID: 22908172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.
    Toniutto P; Fabris C; Fumo E; Apollonio L; Caldato M; Avellini C; Minisini R; Pirisi M
    J Gastroenterol Hepatol; 2005 Apr; 20(4):577-82. PubMed ID: 15836706
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients.
    Sacchi A; Agrati C; D'Offizi G; Vlassi C; Rozera G; Abbate I; Capobianchi MR; Martini F
    Clin Immunol; 2011 Feb; 138(2):178-86. PubMed ID: 21130688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection.
    Kneteman NM; Asthana S; Lewis J; Dibben C; Douglas D; Nourbakhsh M; Tyrrell LJ; Lund G
    Liver Transpl; 2012 Jan; 18(1):38-44. PubMed ID: 21837737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection.
    Graham CS; Wells A; Liu T; Sherman KE; Peters M; Chung RT; Bhan AK; Andersen J; Koziel MJ;
    AIDS; 2006 Feb; 20(3):345-51. PubMed ID: 16439867
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C.
    Scherzer TM; Staufer K; Novacek G; Steindl-Munda P; Schumacher S; Hofer H; Ferenci P; Vogelsang H
    Aliment Pharmacol Ther; 2008 Sep; 28(6):742-8. PubMed ID: 19145730
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interleukin-2 receptor antagonist immunosuppression and consecutive viral management in living-donor liver transplantation for human immunodeficiency virus/hepatitis C-co-infected patients: a report of 2 cases.
    Maki H; Kaneko J; Akamatsu N; Arita J; Sakamoto Y; Hasegawa K; Tanaka T; Tamura S; Sugawara Y; Tsukada K; Kokudo N
    Clin J Gastroenterol; 2016 Feb; 9(1):32-7. PubMed ID: 26661842
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.
    Jain MK; Adams-Huet B; Terekhova D; Kushner LE; Bedimo R; Li X; Holodniy M
    J Viral Hepat; 2015 Jan; 22(1):25-36. PubMed ID: 24506344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study.
    Deltenre P; Canva V; El Nady M; François C; Castelain S; Dharancy S; Louvet A; Bocket L; Lazrek M; Hollebecque A; Wartel F; Henrion J; Duverlie G; Mathurin P
    J Viral Hepat; 2009 Jul; 16(7):500-5. PubMed ID: 19457138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation.
    Moreno Planas JM; Rubio Gonzalez E; Boullosa Graña E; Garrido Botella A; Barrios Peinado C; Lucena Poza JL; Jiménez Garrido M; Sanchez Turrion V; Cuervas-Mons Martinez V
    Transplant Proc; 2005 Jun; 37(5):2207-8. PubMed ID: 15964380
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Dynamic changes in programmed death-1 expression on the surface of T cells in chronic hepatitis C patients undergoing interferon therapy].
    Dong RQ; Zhou DF; Han R; Zhou JY; Zhao CY; Zhen Z
    Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):899-902. PubMed ID: 24636290
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Response-adjusted alpha-interferon therapy for chronic hepatitis C in HIV-infected patients.
    Prestileo T; Mazzola G; Di Lorenzo F; Colletti P; Vitale F; Ferraro D; Di Stefano R; Cammà C; Craxì A
    Int J Antimicrob Agents; 2000 Nov; 16(3):373-8. PubMed ID: 11091068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment.
    Legrand E; Neau D; Galperine T; Trimoulet P; Moreau JF; Pitard V; Lacut JY; Ragnaud JM; Dupon M; Le Bail B; Bernard N; Schvoerer E; Houghton M; Fleury H; Lafon ME
    J Infect Dis; 2002 Aug; 186(3):302-11. PubMed ID: 12134226
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High interferon-stimulated gene ISG-15 expression affects HCV treatment outcome in patients co-infected with HIV and HCV.
    Katsounas A; Hubbard JJ; Wang CH; Zhang X; Dou D; Shivakumar B; Winter S; Schlaak JF; Lempicki RA; Masur H; Polis M; Kottilil S; Osinusi A
    J Med Virol; 2013 Jun; 85(6):959-63. PubMed ID: 23588721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
    Gonzalez VD; Falconer K; Michaëlsson J; Moll M; Reichard O; Alaeus A; Sandberg JK
    Clin Immunol; 2008 Jul; 128(1):46-56. PubMed ID: 18495540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.
    Thomas RM; Brems JJ; Guzman-Hartman G; Yong S; Cavaliere P; Van Thiel DH
    Liver Transpl; 2003 Sep; 9(9):905-15. PubMed ID: 12942451
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future.
    Cammà C; Petta S
    J Hepatol; 2009 Apr; 50(4):648-51. PubMed ID: 19231012
    [No Abstract]   [Full Text] [Related]  

  • 59. [Impact of pegylated interferon alpha and ribavirin therapy of chronic hepatitis C on peripheral blood and intrahepatic lymphocytes].
    Tomasiewicz K; Modrzewska R; Korobowicz E
    Pol Merkur Lekarski; 2009 Jan; 26(151):19-23. PubMed ID: 19391501
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project.
    Lindenburg CE; Lambers FA; Urbanus AT; Schinkel J; Jansen PL; Krol A; Casteelen G; van Santen G; van den Berg CH; Coutinho RA; Prins M; Weegink CJ
    Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):23-31. PubMed ID: 21042221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.